share_log

MIRA Pharmaceuticals | 8-K: Current report

SEC ·  Oct 26, 2024 04:03

Summary by Moomoo AI

MIRA Pharmaceuticals announced that its novel oral ketamine analog, Ketamir-2, demonstrated 60% greater efficacy compared to FDA-approved gabapentin in a preclinical model of chemotherapy-induced neuropathic pain. This result reinforces previous preclinical successes in establishing Ketamir-2's potential as a breakthrough treatment for neuropathic pain.The company is expanding its development program with additional studies focusing on diabetic neuropathy and PTSD. As part of its broader strategy, MIRA is also exploring government funding opportunities to support the program's advancement.
MIRA Pharmaceuticals announced that its novel oral ketamine analog, Ketamir-2, demonstrated 60% greater efficacy compared to FDA-approved gabapentin in a preclinical model of chemotherapy-induced neuropathic pain. This result reinforces previous preclinical successes in establishing Ketamir-2's potential as a breakthrough treatment for neuropathic pain.The company is expanding its development program with additional studies focusing on diabetic neuropathy and PTSD. As part of its broader strategy, MIRA is also exploring government funding opportunities to support the program's advancement.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more